5-fluorouracil chemowraps for the treatment of multiple actinic keratoses
- 48 Downloads
Few satisfactory treatment options are available for widespread areas affected by multiple actinic keratoses (AKs).
Our primary objective was to assess the response rate to weekly 5-fluorouracil (5-FU) chemowraps on widespread AK lesions, and secondarily to assess tolerability, the percentage of patients with recurrence and time to recurrence, the response rate for patients with associated Bowen’s disease (BD), and the percentage of squamous cell carcinomas (SCCs) identified after treatment.
Materials & methods
We conducted an open study which included all the patients who had been treated with weekly 5-FU chemowraps in our department over the course of five years for areas of widespread AKs.
The response rate for AKs was 60%, with 20% complete responses among 25 patients after an average of 9.6 sessions (1 to 64). The treatment had to be discontinued because of toxicity in four patients; one case of contact dermatitis, one case of erosive pustular dermatosis, and two cases of Grade 2 irritations. Invasive SCCs were identified in five patients after treatment cessation. The median recurrence-free survival was five months. A 64% response rate was achieved for associated BD.
The weekly application of 5-FU under occlusion seems to be an interesting, well-tolerated therapeutic option for the treatment of widespread AKs.
Key wordsactinic keratosis Bowen’s disease chemowrap fluorouracil occlusion weekly
Unable to display preview. Download preview PDF.
- 13.Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol 2007; 157: 34–40.CrossRefGoogle Scholar
- 16.Anderson L, Jarratt M, Schmieder G, Shumack S, Katsamas J, Welburn P. Tolerability and pharmacokinetics of ingenol mebutate 0.05% gel applied to treatment areas up to 100cm(2) on the forearm(s) of patients with actinic keratosis. J Clin Aesthet Dermatol 2014; 7: 19–29.PubMedPubMedCentralGoogle Scholar